Zaffran, I., Landolina, N., Gaur, P., Lenac Roviš, T., Jonjić, S., Mandelboim, O. ... Levi Schaffer, F. (2022). Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Therapy, 29. (11), 1676-1685. doi: 10.1038/s41417-022-00486-x
Zaffran, Ilan, et al. "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells." Cancer Gene Therapy, vol. 29, no. 11, 2022, pp. 1676-1685. https://doi.org/10.1038/s41417-022-00486-x
Zaffran, Ilan, Nadine Landolina, Pratibha Gaur, Tihana Lenac Roviš, Stipan Jonjić, Ofer Mandelboim, Bernhard B. Singer and Francesca Levi Schaffer. "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells." Cancer Gene Therapy 29, no. 11 (2022): 1676-1685. https://doi.org/10.1038/s41417-022-00486-x
Zaffran, I., et al. (2022) 'Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells', Cancer Gene Therapy, 29(11), pp. 1676-1685. doi: 10.1038/s41417-022-00486-x
Zaffran I, Landolina N, Gaur P, Lenac Roviš T, Jonjić S, Mandelboim O, and sur.. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Therapy [Internet]. 2022 June 09 [cited 2024 October 04];29(11):1676-1685. doi: 10.1038/s41417-022-00486-x
I. Zaffran, et al., "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells", Cancer Gene Therapy, vol. 29, no. 11, pp. 1676-1685, June 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:520126. [Accessed: 04 October 2024]